Analysts Set Septerna, Inc. (NASDAQ:SEPN) Target Price at $26.75

Key Points

• Septerna, Inc. (NASDAQ:SEPN) has received a consensus rating of “Moderate Buy” from analysts, with an average price target of $26.75.
• Recent upgrades from various analysts include Wells Fargo raising the target price to $18.00 and HC Wainwright setting it at $26.00, signaling positive sentiment around the stock.
• Despite these upgrades, Septerna reported disappointing quarterly earnings, missing consensus estimates significantly with earnings per share of ($0.56) against expectations of ($0.05).

Septerna, Inc. (NASDAQ:SEPN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $26.75.

A number of equities research analysts recently issued reports on SEPN shares. HC Wainwright reissued a "buy" rating and set a $26.00 price target on shares of Septerna in a research note on Thursday, August 21st. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of Septerna in a research note on Friday, September 5th. Finally, Wall Street Zen lowered Septerna from a "hold" rating to a "sell" rating in a research note on Saturday.

Septerna Price Performance

Shares of NASDAQ:SEPN traded down $0.14 during trading on Wednesday, hitting $14.14. The company had a trading volume of 30,908 shares, compared to its average volume of 637,668. The stock has a market cap of $630.36 million and a price-to-earnings ratio of -1.40. Septerna has a one year low of $4.17 and a one year high of $28.99. The company has a fifty day simple moving average of $12.47 and a two-hundred day simple moving average of $9.46.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. On average, equities research analysts anticipate that Septerna will post -7.11 earnings per share for the current year.

Institutional Investors Weigh In On Septerna

A number of institutional investors and hedge funds have recently modified their holdings of SEPN. Tower Research Capital LLC TRC bought a new stake in shares of Septerna during the 4th quarter worth approximately $25,000. The Manufacturers Life Insurance Company bought a new position in shares of Septerna during the 4th quarter worth $506,000. Northern Trust Corp purchased a new position in shares of Septerna during the fourth quarter valued at $3,384,000. Jane Street Group LLC purchased a new position in shares of Septerna during the fourth quarter valued at $600,000. Finally, BNP Paribas Financial Markets purchased a new position in shares of Septerna during the fourth quarter valued at $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.